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The neuraminidase (NA) in viral surface is one of the main subtype-specific antigen of influenza type A viruses. Neuraminidase is 
an enzyme to break the bonds between hemagglutinin (HA) and sialic acid to release newly formed viruses from infected cells. In 
this study, the H3N2 subtype virus NA genes were sequenced and NA proteins were screened for B-cell epitopes and assessed 
based on immunoinformatics. Based on this results, four peptides DR6, EY7, VG8 and RE8 (covering amino acid residues 
151–156, 368–374, 398–405 and 428–435, respectively) of the NA protein were synthesized artificially. These peptides were used 
to immunize New Zealand rabbits subcutaneously to raise antisera. Experimental results showed that these four peptides were 
capable of eliciting antibodies against H3N2 viruses in a specific and sensitive feature, detected in vitro by enzyme-linked im-
munosorbent assay. Moreover, hemadsorption anti-releasing effects took place in three three-antisera-mixtures at a dilution of 
1:40. Alignment using NA gene database showed that amino acid residues in these four epitope peptides were substituted at spe-
cific sites in all the NAs sequenced in this study. It was suggested that these NA epitope peptides might be used in combination 
with HA proteins as vaccine antigens. 
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The severity of influenza A virus infections varies depend-
ing on their host’s acquired immunity. A novel antigenic 
variant of influenza A H3N2 subtype virus resulted in mil-
lions of deaths worldwide in influenza pandemic in 1968 [1]. 
Since then, the predominant circulating influenza A virus 
almost has been the influenza H3N2 subtype [2].  
The two proteins in the dominant circulating H3N2 virus 
are the H3 hemagglutinin (HA) and N2 neuraminidase (NA) 
surface glycoproteins. HA protein is encoded by influenza 
gene segment 4 and NA is encoded by segment 6, and both 
proteins are subtype specific. HA binds to sialic acid (SA)- 
containing receptors on target cells to initiate virus infection, 
whereas NA cleaves sialic acid from cell receptors and from 
extracellular inhibitors to facilitate the release of progeny 
virus and to promote the spread of the infection to neigh-
boring cells [3]. HA and NA having closely related func-
tions must be “perfectly balanced” to allow the virus to be 
infectious. The original discovery of NA showed that it had 
a role as the determinant of “receptor-destroying” activity of 
free virus in hemagglutination reactions, which reinforced 
the focus on virion-associated NA in virion release. Later 
studies also reported the role of NA in cleavage of SA in the 
extracellular space [4]. The oseltamivir and zanamivir, two 
NA inhibitors, used in the current clinical treatment of  
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influenza A virus infection are based on its “receptor-destroy-   
ing” activity on the cell surface as oseltamivir carboxylate 
(the active form of Tamiflu) and zanamivir (Relenza) are 
SA analogs that interfere with the sialidase activity of NA 
[4].  
Five epitope peptides have previously been identified by 
us in NA from the 2009 pandemic H1N1 virus with hemag-
glutination-inhibition antibody titers that ranged from 1:40 
to 1:80 [5]. In this study, we characterize H3N2 viruses 
isolated from suspected patients’ throat swabs in Guang-
dong province (China) and sequence the NA gene sequenc-
es from the strains. Using the SPSS (stepwise prediction and 
statistical screening) strategy [6], a bioinformatics (im-
munoinformatics) method, we predicted and screened B-cell 
epitopes in H3N2 virus NA. The predicted epitope peptides 
were synthesized artificially and rabbit antisera against the 
epitope peptides were collected, which contained antibodies 
specific to NA protein. Both the specificity and sensitivity 
of epitope peptides and virus strains were measured by en-
zyme-linked immunosorbent assay (ELISA). The objects in 
this study is to learn the epitope and its function of H3N2 
virus NA gene. Research into and application of im-
munoinformatics is considered to accelerate the develop-
ment of epitope-based vaccines [7]. 
1  Materials and methods 
1.1  Viruses and cells  
Influenza A H3N2 viruses amounted to 17 strains isolated 
from Guangdong from 2007 to 2010; NA gene sequences 
from these have been determined (even numbers in Gen-
Bank accession numbers CY091826–CY091858). The vi-
ruses were used for animal inoculation and antiserum pro-
duction as well as for viral RNA preparation. For inocula-
tion, the viruses were cultured and grown in 10-d-old em-
bryonated eggs; and for other applications, they were grown 
in Madin-Darby canine kidney (MDCK) cells (ATCC, Ma-
nassas, USA). The cells were propagated in Dulbecco’s 
modified Eagle medium (DMEM; Invitrogen, Carlsbad, 
USA) supplemented with 10% fetal bovine serum (FBS; 
Sijiqing Corporation, Hangzhou, China), 100 U/mL of pen-
icillin and 100 μg of streptomycin (Invitrogen) with 5% 
CO2 in humidified air at 37°C. Sequences of the other 50 
reference NA genes were downloaded from GenBank and 
LANL databases (http://www.flu.lanl.gov). 
1.2  NA gene sequencing 
Three pairs of primers were designed using the Primer 
Premier 5.0 software and synthesized according to the NA 
gene sequences of influenza A H3N2 viruses isolated from 
1968 to 2010. Primer sequences are as follows: P-NAF1 
(5′-AGCARAAGCAGGAGT-3′), P-NAR1 (5′-TCGTGAC-     
AACTTGAGCTGGAC-3′); P-NAF2 (5′-TATCAATTTGC-     
MCTTGGRCAGG-3′), P-NAR2 (5′-TCCCATCCACACRT-      
CATTTCC-3′); and P-NAF3 (5′-TATCAATTTGCMCTTG-      
GRCAGG-3′), P-NAR3 (5′-TCCCATCCACACRTCATTT-      
CC-3′) [6]. Total viral RNA was isolated from 140 µL of 
viral suspension using the QIAamp Viral RNA kit (Qiagen, 
Hilden, Germany). Then 2 L of RNA was added to a total 
of 50 L reaction mixture that contained 10 L of 5× 
OneStep reverse transcription polymerase chain reaction 
(RT-PCR) buffer (Qiagen; 0.5 mmol/L), 1 L of dNTP, 1 
L of enzyme, 1 L of forward (F) and reverse (R) primers 
respectively (25 mol/L), and 34 L of RNase-free H2O. 
Reaction mixtures were incubated at 50°C for 30 min and 
94°C for 5 min, and then a total of 35 cycles at 94°C for  
30 s, 45°C for 30 s and 72°C for 90 s. The PCR products 
were purified with a gel extraction kit (Qiagen) and se-
quenced on an ABI PRISM 3100 Genetic Analyzer with an 
ABI PRISM BigDye Terminator V3.0 ready reaction cycle 
sequence kit (Applied Biosystems, Foster City, USA) ac-
cording to the manufacturer’s instructions. 
1.3  Epitope prediction, screening and assessment 
DNA sequences were compiled using the Lasergene 7.1 
software (DNASTAR Inc., Madison, USA) and multiple 
sequence alignments were assembled with MEGA 5.03 
software. The -helix, -fold, -turn, coil, flexible region, 
hydrophilicity plot, surface probability plot and antigenic 
index (AI) were predicted based on the NA amino acid se-
quence of A/Guangdong/15/2007 (H3N2) (for short GD-15- 
2007). Neuraminidase proteins were screened for B-cell 
epitopes based on the analysis of their protein features and 
using hierarchical clustering methods, Spearman’s correla-
tion and quartiles using Protean 7.1 and SPSS 16.0 (SPSS 
Inc., Chicago, USA). Antigenic index and the average AI 
(AAI) values were acquired [6]. 
1.4  Homology modeling 
The 44 NA sequences were totally included in this study, 
which included 17 Guangdong strain NA sequences and 27 
NA sequences downloaded from the GenBank database. 
Homology modeling was performed using the SWISS- 
MODEL molecular simulation software [8]. Molecular 
three-dimensional structure of the epitope peptides was 
shown by YASARA [9], in which the location of each 
epitope peptide sequence was labelled. 
1.5  Peptide synthesis 
The epitope peptides were synthesized artificially and then 
coupled to keyhole limpet hemocyanin (KLH). Some epitope 
peptides needed to be modified with cysteine (C) at the 
C-terminus or N-terminus end dependent upon their peptide 
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features in order to ease coupling to KLH. 
1.6  Antiserum preparation 
The serum antibody to strain GD-15–2007 was prepared, 
which was propagated in 10-d-old embryonated eggs. Two 
adult New Zealand rabbits were immunized by injection of 
these mixtures subcutaneously: 50% emulsion of Freund’s 
complete adjuvant with either 50 g of each conjugated 
synthetic peptide or -propiolactone (BPL)-inactivated flu 
strain (allantoic fluid hemagglutination titer of 1:64). Four 
booster doses in a 50% emulsion with Freund’s incomplete 
adjuvant were given at 2-week intervals. Antisera were col-
lected after the last immunization on the seventh day. 
1.7  Peptide identification with ELISA 
Antibody titers against each synthetic peptide and the virus 
were measured by ELISA [10]. In detail, 96-well microtiter 
plates were coated overnight at 4°C with 100 L of 0.05 
mol/L phosphate-buffered saline (PBS; pH 9.6) that con-
tained 50 g/mL of unconjugated synthetic peptides or 1 
hemagglutination unit (HAU) (strain GD-15–2007 propa-
gated in MDCK cells). The pre-immunization serum was 
used as the negative control. The plates were washed with 
PBS three times, blocked with 3% bovine serum albumin 
(BSA) and incubated with 100 L of antiserum at serial 
dilutions at 37°C for 1 h and then washed three times with 
PBS that contained 0.1% Tween-20. Detection was per-
formed using the secondary antibody horseradish peroxidase- 
conjugated goat anti-rabbit IgG (H+L) (Scicrest, Beijing, 
China; dilution 1:6000) at 37°C for 1 h. Then the plates were 
washed three times. The color was developed with O-pheny-    
lenediamine dihydrochloride substrate (Sigma, St. Louis, 
USA) and the absorbance was read at 450 nm wavelength 
with an ELISA plate reader (Molecular Devices, San Jose, 
USA). Each assay was performed independently three times. 
Epitope peptides were coated to microtiter plates and the 
excess washed off, then 50 g/mL of polylysine and 1 mol/L 
of glycine were added in serial dilutions to each well. The 
cut-off value was determined for each peptide by incubation 
with sera from five normal rabbits (pre-immunization). 
1.8  Hemagglutination-inhibition (HI) assays and HI- 
releasing 
Using 1.0% rooster red blood cells (RRBCs), these assays 
were performed as described previously [11]. For HI assays, 
50 L of a two-fold serial dilutions of the antisera samples 
in PBS were incubated at 4°C for 1 h with an equal volume 
of 4 HAU of the virus antigen (GD-15–2007), followed by 
the addition of 50 L of 1.0% RRBCs. The highest dilution 
of the antibody that showed no hemagglutination was con-
sidered to HI titer. Observation for HI and HI-releasing  
effect was made after 30 min, 1, 2, 3, and 4 h at 22°C. 
1.9  Variation and entropy 
For the purpose of analysing the amino acid variations of  
44 NA proteins by MEGA 5.05, the most recent common 
ancestor (MRCA) was considered to be the NA gene of A/ 
Hong Kong/1/68 (H3N2) and reference virus was taken to 
be the NA gene of A/Wyoming/3/2003 (H3N2) [2]. Entropy 
plots were made using BioEdit 7.09 software and the en-
tropy value was taken to indicate the statistically variable 
probability [12]. 
2  Results 
2.1  NA gene variation 
The 469 amino acids were encoded by 1410 NA nucleotides 
from GD-15-2007, with a 45.4 kD weight and pH 6.1 as the 
isoelectric point (IP). The ratios of basic, acidic, hydropho-
bic and polar amino acids in the NA proteins were 9.6%, 
11.1%, 29.6% and 33.9%, respectively. Taken the NA gene 
of A/Wyoming/3/2003 as reference, the NA gene substitu-
tion ratio was 13.4% (63/469) in 43 H3N2 viruses from 
1968 to 2003, which included N93D, D147N, H150R, 
V194I, I215V, K221E, Y310H, L370S, N372K, S387L and 
Q432E in most strains and E199K, Q432E in all strains. 
2.2  Epitope prediction, screening and assessment 
B-cell epitopes of NA proteins were predicted by their hy-
drophilicity, the surface probability and the AI, assisted by 
analysis of their secondary structure and their flexible re-
gions. The Spearman’s correlation, Hierarchical clustering 
and their quartiles were used to analyze the epitopes and the 
SPSS strategy was used to screen and assess. The AAI score 
values of the epitope peptides were 0.009–0.082 (Table 1).  
Before immunization to produce antibodies, DR6 was 
decorated by cysteine at C-terminal, and EY7 and RE-8 
were decorated by cysteine at N-terminal, which made it 
easy to couple KLH. 
2.3  Three-dimensional modeling 
The N2 neuraminidase monomer of GD-15-2007 obtained  
Table 1  Epitope peptides screened by stepwise prediction and statistical 
screening (SPSS)a) 
Peptide Position Sequence Total AI AAI 
DR6 151–156 DRTPYR 0.493 0.082 
EY7 368–374 EKLRSGY 0.061 0.009 
VG8 398–405 VDGRNRSG 0.443 0.055 
RE8 428–435 RGRKEETE 0.441 0.051 
a) AI, antigenic index; AAI, average antigenic index. 
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using SWISS-MODEL showed that 2aepA in the Protein 
Data Bank (PDB) had the highest sequence homology 
(94.6% identity) at amino acid residues from 82 to 469, with 
2.10 Å X-ray resolution. The final structure was further 
evaluated by YASARA, which is normally used to quantify 
the compatibility of an amino acid sequence with a three- 
dimensional protein structure and especially to check the 
validity of a hypothetical epitope peptide structure (Figure 
1). The peptides DR6, EY7, VG8 and RE8 were labelled on 
the surface of the molecular three-dimensional structure. 
2.4  Epitope sensitivity 
Either the virus antigen (1 HAU of GD-15-2007 passaged 
by MDCK cells, which was inactivated by -propiolactone) 
or each epitope peptide was bound to 96-well plates over-
night at 4°C with 100 L of antiserum (dilution of 1:100, 
1:1000, 1:10000, 1:20000, 1:40000, 1:80000) in car-
bonate–bicarbonate buffer (pH 9.6). The H3N2 virus GD- 
15-2007 in ELISA results was shown to be able to detect 
against the anti-strain GD-15-2007 serum at a maximum 
dilution of 1:40000 and the anti-epitope serum at a maxi-
mum dilution of 1:20000. The plates coated with each 
epitope peptide were able to detect the corresponding anti- 
epitope serum at a maximum dilution of 1:10000 and 
1:20000 (Table 2). High sensitivities were shown in detec-      
tive results between the immunogens (including viron and 
peptides) and their antisera. The positive was regarded in 
ELISA detection when the detected antiserum value was 
higher than the cut-off value determined by pre-immunization 
serum at a dilution of 1:100.  
2.5  Epitope specificity 
Either the antigen seasonal inactivated H1N1 (GD-1-2007) 
or the antigen 2009 A H1N1 (GD-801-2009) virus was 
coated to ELISA microtiter plates (96-well plates, 1 HAU), 
then cross-reacted with antisera against the epitope peptides. 
The plates coated with the seasonal H1N1 virus or the 2009 
H1N1 virus were able to detect each anti-epitope peptide 
serum at a dilution of 1:200 or less (Table 2). The high 
specificities were shown in results between the immunogens 
and their antisera.  
2.6  HI assay and anti-releasing effects 
Hemagglutination was conducted in U-shaped bottom 96- 
well plates incubated with 4 HAU of virus GD-15-2007,  
 
Figure 1  (Color online) Three dimensional neuraminidase (NA) (N2) models of four epitope peptides. (a) Each epitope sequences (DR6, EY7, VG8 and 
RE8 for a1, a2, a3 and a4, respectively) are in molecular surface; (b) four epitope sequences are labelled. 
Table 2  Immunosensitivity and immunospecificity between epitope peptides and antisera 
Immunogen 
Antisera titera) 
Anti-virion Anti-DC7 Anti-CY8 Anti-VG8 Anti-RE8 
Immunosensitivity      
Virion (H3N2)b) 1:40000 1:20000 1:20000 1:20000 1:20000 
DR6 1:10000 1:20000 1:100 1:100 1:100 
EY7 1:10000 1:200 1:10000 1:100 1:100 
VG8 1:20000 1:100 1:100 1:20000 1:100 
RE8 1:20000 1:100 1:100 1:200 1:20000 
Immunospecificity      
GD-1-2007 (seasonal H1N1) – 1:200 1:200 1:100 1:200 
GD-801-2009 (2009 A H1N1) – 1:100 <1:100 <1:100 <1:100 
a) The diluent titer of rabbit serum before immunization against the immunogen was less than 1:100; b) strain H3N2 was GD-15-2007.  
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antisera to epitope peptides and 1% RRBCs; however no 
effect was observed in the plates incubated with 4 HAU of 
virus, antiserum to virus GD-15-2007 and 1% RRBCs. Ti-
ters of diluted antiserum to virus or each epitope peptide 
were measured by HI assay. Results showed that when the 
titer of antiserum to virus GD-15–2007 reached 1:320, it 
reacted with the virus GD-15-2007 (Table 3). No HI reaction 
took place with any of the antisera against epitope peptides. 
The hemadsorption anti-releasing effect observed after 4 
h at 22°C in the three three-antisera-mixtures at a dilution of 
1:40, while the hemadsorption releasing effects of RRBCs 
only was seen in the negative controls (pre-immunized sera 
from rabbits). 
2.7  Variation of epitope peptides 
The reference virus was taken to be A/Kong Hong/1/68 
virus. For the four predictive epitope peptide sequence re-
gions, amino acid substitutions occurred in 44 sequences at 
D151V/N, I153T and H155Y for DR06, K368E, D369K/T, 
L370S and S372L/F for CY07, S400R/K, D401G and 
R402D for VG8 and R430S, Q432E, T434N and R435E for 
RE8 (Figure 1) and the entropy values of four peptide sub-
stitution sites were shown (Table 4). 
3  Discussion 
Antigenic determinants considered to be B-cell epitopes, are  
Table 3  Hemagglutination-inhibition (HI) assay and anti-releasing effects 
Antisera 
HAa) 
(at 40 min) 
HI 
Anti-releasing effects 
(22°C, after 4 h) 
Anti-viron – 1:320b) ± 
Antisera mixture Ac) + – 1:40 
Antisera mixture B + – 1:40 
Antisera mixture C + – 1:40 
a) HA, hemagglutination. b) Diluent titer of serum. c) Antisera mixture 
A, anti-DR6, anti-EY7 and anti-VG8; antisera mixture B, anti-DR6, anti- 
EY7 and anti-RE8; antisera mixture C, anti-DR6, anti-VG8 and anti-RE8. 
Table 4  Entropy values of the influenza H3N2 virus neuraminidase site 
from years 1968 to 2010 
Peptide Position Entropy Peptide Position Entropy 
DR6 151 0.392 VG8 400 0.545 
 153 0.183  401 0.551 
 154 0.078  402 0.211 
 155 0.302    
EY7 368 0.183 RE8 430 0.134 
 369 1.001  431 0.496 
 370 0.723  434 0.432 
 372 0.760  435 0.575 
recognized and bound by membrane-associated receptors on 
the surface of B lymphocytes. The B-cell epitopes can be 
classified into two types: linear (continuous) and conformat-     
ional (discontinuous) epitopes. Linear epitopes are short 
peptides that correspond to contiguous amino acid sequenc-
es within a protein, however, conformational epitopes usu-
ally are composed of several discontinuous amino acids or 
peptides. Immuno-informatics to determine solvent accessi-
bility, secondary structure and flexibility has been used in 
recent years to screen B-cell epitopes [7,8]. Homology 
modeling is based on the prediction of epitopes from the 
primary structure of proteins, and makes the results accurate 
and reliable, which is a useful method to predict the struc-
ture of unknown proteins, and represents a new direction for 
structure-based epitope-prediction technology [5]. Accord-
ing to previous assays, the AI and AAI values of the epitope 
using SPSS did not directly correlate with the antibody ac-
tivity, but they seemed to have other connections. 
Seven epitopes of N2 NA protein were identified in a 
previous assay as follows: site 153, 197–199, 328–336, 
339–347, 367–370, 400–403 and 431–434; the enzyme ac-
tive site of NA protein was found to include amino acid 
sites 119, 156, 178, 179, 198, 222, 227, 274, 277, 294 and 
425 [13]. In this study, four epitopes (peptides 151–156, 
368–374, 398–405 and 428–435) were determined that cov-
ered previously reported epitope sites (153, 367–370, 400– 
403 and 431–434), but had changes in length and peptide 
sequence to some degree. Therefore their antigenicity needed 
re-identification, as one amino acid at position 153 was too 
short alone to act as a sole epitope but might form part of 
conformational epitope. The four epitope sequences in this 
study were different from previous three epitope sequences, 
but four epitopes functioned the similar biological effects 
[12]. The specific function of each epitope sequence is 
worthy of further identification.   
The epitopes as the centre of anti-infectious immunity, 
related to viral antigen and their antibodies still are the 
highlights of infectious disease control and prevention, but 
it is also needed that development of an immunoinformatics 
method combined with comprehensive analysis on subse-
quent experiments. Four synthetic peptides, DR6, EY7, 
VG8 and RE8, were designed based on the primary se-
quence of the NA protein determined by SPSS analysis. 
Analysis of the sequences of the NA genes from 44 virus 
strains showed that these four epitopes were located on sur-
face of the NA protein and formed part of the three-dimen-    
sional structure. The KLH-conjugated synthetic peptides 
were injected into New Zealand rabbits, and then biological 
activities of the antisera and the corresponding antigens 
were determined. These four synthetic peptides showed 
clear sensitivities to the corresponding antisera and had dis-
tinct specificities compared with other subtype viruses in 
vitro. Although the diluent titers of the epitope peptide an-
tibodies were lower than those of the virion (1:10000 vs 
1:20000), these results were still clinically and biologically 
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significant. 
The NA molecule, especially its epitopes, is located on 
the outer surface of the influenza virion and spans the lipid 
layer. NA acts as an enzyme to cleave SA 2,6- or 2,3-glyco-      
sidic bonds from the HA molecules at the virus surface, and 
this action results in release of virus particles from the host 
cells. Therefore, the new released virion is capable to infect 
other host cells, which results in the spread of virus infec-
tion. The mechanism of antisera anti-releasing effects might 
be that the virus cleaving activity had been influenced by 
the antisera attaching to epitope peptides of a virion [5,14]. 
The higher entropy values of the four peptide sites in this 
study indicated that the epitope amino acid sites were bore 
on the natural or immunological pressure. As NA protein 
has an important biological role in influenza, epitope muta-
tions might influence the make-up of the dominant circulat-
ing influenza virus, and therefore epidemic and vaccine 
selection.  
Nowadays, the HA protein is usually the influenza vac-
cines against epidemic and pandemic influenza viruses. 
However, because NA has an important function in influ-
enza pathogenesis and spreading, their B-cell epitopes might 
be candidates for influenza vaccines. It was believed that the 
combination of HA and NA (or with epitope peptides) as a 
vaccine benefited the effects of influenza vaccination [7]. 
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